Enanta reports Q3 fiscal 2021 net loss of $24.0M; nominates COVID-19 protease inhibitor EDP-235

ENANTA PHARMACEUTICALS INC

2021-Q3 EPS reported -$2.70 revenue$73,499,000

Royalty revenue $21.6M from AbbVie's HCV regimen; net loss $24.0M ($1.19/sh) vs loss $14.3M ($0.71/sh) year ago.
Cash and securities $372.5M; R&D expenses increased to $47.0M from $34.7M.
Nominated EDP-235 oral protease inhibitor for SARS-CoV-2; Phase 1 study planned for early 2022.
Positive Phase 1b data for EDP-514 in viremic HBV patients: mean HBV DNA reduction 3.3 logs.
Planned retirement of CMO Nathalie Adda, M.D. in February 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.